Genetics in TNF-TNFR pathway: A complex network causing spondyloarthritis and conditioning response to anti-TNFα therapy

Ada Aita1*, Daniela Basso1*, Roberta Ramonda2, Stefania Moz1, Mariagrazia Lorenzin2, Filippo Navaglia1, Carlo-Federico Zambon3, Andrea Padoan1, Mario Plebani1, Leonardo Punzi2

1 Laboratory Medicine, Department of Medicine-DIMED, University-Hospital of Padua, Padua, Italy, 2 Rheumatology Unit, Department of Medicine-DIMED, University-Hospital of Padua, Padua, Italy, 3 Department of Biomedical Sciences-BIOMED, University of Padua, Padua, Italy

* These authors contributed equally to this work.

Abstract

Objectives

We investigated whether polymorphisms (SNPs) in the promoter region of TNFA, or in the autoinflammatory TNFRSF1A and MEFV genes, concur with HLA-B27 in enhancing the risk of Spondyloarthritis (SpA) and/or in predicting the response to anti-TNFα treatment.

Methods

373 controls and 137 SpA (82 with Psoriatic Arthritis-PsA and 55 with Ankylosing Spondylitis-AS; 98/137 under TNFα inhibitor therapy) from the Veneto Region (Italy) were studied. TNFA polymorphisms (-1031T>C;-857C>T;-376G>A;-308G>A;-238G>A) and HLA-B27 were assayed by RT-PCR. Direct sequencing of MEFV (exons 2,3,5 and 10) and TNFRSF1A (exons 2,3,4 and 6) genes were performed.

Results

HLA-B27 was associated with AS ($\chi^2 = 120.1; p = 0.000$). Only the TNFA -1031T>C was singly associated with SpA, and the haplotype C/G, resulting from -1031T>C/-308G>A combination, was significantly associated with a reduced risk of SpA (OR: 0.67, CI: 0.46–0.97; p = 0.035). Two SNPs were identified in TNFRSF1A, the R92Q (Minor allele frequency-MAF = 0.034) and c.625+10A>G (MAF = 0.479). None of them was associated with SpA (p>0.05). The TNFRSF1A c.625+10 G allele was associated with late response to anti-TNFα therapy (p = 0.031). Twenty-one SNPs were identified in MEFV gene, 10 with a known potential functional significance. Variant alleles were extremely rare in our population (MAF<0.025) except for R202Q (MAF = 0.27). None was associated with SpA diagnosis (p>0.05).
Conclusion

TNFRSF1A and MEFV gene SNPs are not associated with SpA in the North-East of Italy. AS risk appears to depend not only on HLA-B27, but also on the protective TNFA haplotype -1031C/-308G. The TNFRSF1A c.625+10A>G impacts on the response to anti-TNFα therapy.

Introduction

The spondyloarthritis (SpA), a group of chronic inflammatory diseases affecting the sacro ileal joint that includes the two major subtypes Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA), results from a complex interplay among genetic background and environmental factors, that leads to the activation of autoinflammation and dys-regulation of the immune-system. Two main groups of SpA have been defined, axial and peripheral SpA, the latter being characterized by the involvement of less than five peripheral joints occurring before, at the same time or after the onset of axial SpA [1,2].

At onset of disease, usually occurring at a young age, SpA diagnosis might be delayed because of the overlap of clinical features and absence of specific blood biomarkers. Although increased serum levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), cytokines, vascular endothelial growth factor (VEGF), calprotectin and matrix metalloprotease-3 (MMP3) might be observed in SpA patients, these biomarkers have limited specificity and sensitivity, because they are common markers of systemic inflammation and their increase parallels disease activity [3,4]. The delayed SpA diagnosis, estimated to be 8–11 years, underlies a retard in treatment and imparts a tremendous symptomatic burden and loss of function in these patients during the productive years of life [5].

The delay in diagnosis, the lack of specific diagnostic and prognostic biomarkers and of complete clinical response even after therapy with tumor necrosis factor α (TNF-α) inhibitors, such as etanercept, infliximab, adalimumab and golimumab, have raised the interest in the pathogenetic mechanism involved in SpA diseases, with the aim also of identifying biochemical and genetic biomarkers that might help the diagnostic work up and the evaluation of treatment effectiveness [6].

Genes in major histocompatibility complex (MHC) and non-MHC locus have been claimed to play a role in pathogenesis of SpA. The MHC accounts for about 40–50% of the genetic risk of developing SpA, 30% of the total heritability being related to the human leukocyte antigen (HLA)-B27 haplotype [7]. Single nucleotide polymorphisms (SNPs) in genes involved in TNF-α signalling, as those in the promoter region of TNFA gene, in TNFSF15 (TNF ligand superfamily, member 15), TNFR-1 (TNF receptor 1) and TRADD (TNF receptor type 1-associated death domain protein), have been identified as potentially associated with SpA [8–13]. This is of great interest because TNF-α is not only involved in the propagation and perpetuation of inflammation in SpA, but also because of the clinical efficacy of treatments based on drugs targeting the TNF-α pathway [14,15]. Taking into consideration the potential role of autoinflammation in disease pathogenesis, other potential candidates are the MEFV (Mediterranean fever) and TNFRSF1A (TNF receptor superfamily member 1A) genes, involved in the pathogenesis of the autoinflammatory disorders Familial Mediterranean Fever (FMF) and Tumor necrosis factor Receptor-Associated Periodic Syndrome (TRAPS) respectively [16,17]. The latter gene encodes the TNFR-1 and genetic variations might underlie functional alterations of the TNF-α signalling, while variations in MEFV gene were shown to be very common among FMF Turkish patients with AS as a sole clinical manifestation [18–24].
The aim of the present study, conducted in 137 SpA patients and 373 controls coming from the North-East of Italy, was to verify whether in addition to the established HLA-B27 genetic predisposing factor, biomarkers of inflammation, SNPs in the promoter region of TNFA, or variants of the autoinflammatory TNFRSF1A and MEFV genes, might be of help in SpA diagnosis and/or in predicting the response to anti-TNFα treatment.

**Patients and methods**

**Ethic statement**

This case-control study was approved by the Institutional Review Board of the University-Hospital of Padova (Protocol number: 3024P/13) and all subjects gave their fully informed written consent at enrolment.

**Study population**

A total of 510 cases and controls, coming from the Veneto Region, a North-East Italian region, were enrolled from January 2014 to December 2017. Cases were 137 SpA patients (84 males, 53 females; mean age ± SD: 51.6 ± 12.6 years) and controls were 373 healthy blood donors (230 males, 143 females; mean age ± SD: 46.5 ± 9.8 years).

Among cases, 55 patients (40%) had a definite diagnosis of AS, according to the modified New York criteria [25] and 82 (60%) had a diagnosis of PsA according to the ClASsification criteria for Psoriatic ARthritis (CASPAR criteria) [26].

All patients underwent clinical, clinimetric and functional examinations following a standardized protocol. Detailed demographic and clinical characteristics of the enrolled patients are shown in Table 1.

At enrolment, 98 patients (71.5%) were under treatment with TNF-α inhibitors (32 Infliximab, 38 Adalimumab, 21 Etanercept, 4 Golimumab, 2 Ustekinumab and 1 Secukinumab) and 16/98 (16.3%) experienced in their clinical history, at least one switch of TNF-α inhibitor before entering the study. Although there is no consensus regarding the criteria to classify the response to TNF-α inhibitors, the European League Against Rheumatism (EULAR) stated that maximal efficacy usually is not seen before 6 months even when improvement is achieved at 3 months, and indicates monitoring every 6–12 months once the treatment target has been attained [27]. Based on these recommendations, we considered 10 months-evaluation an adequate time point to make a final classification of patients as early or late responders, being responders those who reached a Bath Ankylosing Spondylitis Disease Activity Index (BAS-DAI) score lower than/equal to 4, on a scale from 0 (no activity) to 10 (high disease activity), in agreement with Braun et al [28].

**Haematological and biochemical indices**

The complete blood count, ESR, CRP, glucose, uric acid, creatinine, alanine aminotransferase (ALT) and prealbumin were measured by standard laboratory methods.

**Genetic analyses**

Genomic DNA was isolated from EDTA-K₂ peripheral blood (MagNA Pure System, Roche S. p.A., Monza, Italy). HLA-B27 was determined using a commercially available CE-IVD micro-array (EUROArray HLA-B27–Direct, Euroimmun AG, Luebeck, Germany). The genotype discrimination of five TNFA gene SNPs (-1031T>C, rs1799964; -857C>T, rs1799724; -376G>A, rs1800750; -308G>A, rs1800629; -238G>A, rs361525) was performed by a Taq-Man dual probes allelic discrimination assay using ABI Prism 7900 (Applied Biosystem, Foster City, CA, USA).
Exons 2, 3, 4 and 6 of the TNFRSF1A gene were studied using denaturing high-performance liquid chromatography (DHPLC; Wave 2100 Fragment Analysis, Transgenicom, Omaha, NE, USA) and gene sequencing (ABI PRISM 3130 Genetic Analyzer, Applied Biosystem, CA, USA) of identified heteroduplexes as described by us elsewhere [30]. Polymorphisms of the MEFV gene were analyzed by direct sequencing of exons 2, 3, 5 and 10 (Applied Biosystem, CA, USA) as detailed in S1 File and S1 Table. The genotype discrimination of the R202Q SNP (rs224222) in MEFV gene (exon 2) was performed by a TaqMan dual probes allelic discrimination assay (Applied Biosystem, Taqman SNP genotyping, catalogue number C_2394721_10).

All genetic analyses were performed in an exploratory cohort of 91 patients and 27 controls. To improve the estimate of significant associations found at interim analysis in the exploratory cohort, the number of examined controls was extended from 27 to 214 for the HLA-B27 and to 218 for the R202Q SNP in MEFV gene, the maximum number of available biomaterial. The

Table 1. Demographic, clinical characteristics, laboratory indices and outcome measures. The demographic characteristics were those obtained at enrolment, while patients’ clinical data and laboratory indices are referred to findings obtained at diagnosis of AS or PsA disease.

|                          | Controls (n = 373) | AS (n = 55) | PsA (n = 82) | Statistics |
|--------------------------|-------------------|-------------|-------------|------------|
| Demographic characteristics at enrolment |                   |             |             |            |
| Gender (M/F)             | 230/143           | 43/12       | 41/41       | χ² = 1.05  p = 0.004 |
| Age, mean±SD (years)     | 46.46 ± 9.81      | 49.76 ± 13.75 | 52.85 ± 11.66*** | F = 12.47 p < 0.0001 |
| Weight, mean±SD (Kg)    | 77.39 ± 15.55     | 73.19 ± 10.52 | 77.44 ± 13.27 | F = 1.89  p = 0.1523 |
| Height, mean±SD (cm)    | 172.43 ± 9.95     | 174.19 ± 6.56 | 170.63 ± 8.53 | F = 2.35  p = 0.0968 |
| BMI, mean±SD (Kg/m²)    | 26.18 ± 7.28      | 24.06 ± 6.74 | 26.55 ± 4.08 | F = 2.79  p = 0.0623 |
| Clinical characteristics at diagnosis |                   |             |             |            |
| Family history of SpA, n (%) | 17 (33) | 61 (77) | χ² = 25.80  p < 0.0001 |
| Age at diagnosis, mean±SD (years) | 38.59 ± 12.95 | 40.83 ± 12.84 | t = 0.95  p = 0.3325 |
| Inflammatory back pain, n (%) | 50 (98) | 52 (66) | χ² = 19.03  p < 0.0001 |
| Periheral arthritis, n (%) | 11 (21) | 74 (94) | χ² = 72.37  p < 0.0001 |
| Enthesitis, n (%)        | 44 (85)           | 56 (71)     | 3.27        | p = 0.070 |
| Buttock pain, n (%)      | 46 (88)           | 22 (28)     | χ² = 46.15  p < 0.0001 |
| Dactylitis, n (%)        | 1 (2)             | 39 (49)     | χ² = 33.27  p < 0.0001 |
| Uveitis, n (%)           | 3 (6)             | 1 (1)       | χ² = 2.14   | p = 0.143 |
| Psoriasis, n (%)         | 4 (8)             | 66 (84)     | χ² = 72.51  p < 0.0001 |
| IBD, n (%)               | 4 (8)             | 2 (3)       | χ² = 1.91   | p = 0.167 |
| Urethritis/Cervicitis/Diarrhoea, n (%) | 5 (10) | 18 (23) | χ² = 3.75   | p = 0.053 |
| Laboratory indices and outcome measures at diagnosis |                   |             |             |            |
| ESR, mean±SD (mm/hr)     | 23.98 ± 13.79     | 29.74 ± 14.42 | t = 5.19 | p = 0.0244 |
| CRP, mean±SD (mg/L)      | 6.51 ± 5.20       | 8.00 ± 6.07 | t = 2.10    | p = 0.1495 |
| DAS, mean±SD             | 3.46 ± 1.23       | 3.45 ± 0.85 | t = 0.00    | p = 0.9696 |
| BASMI, mean±SD           | 3.76 ± 1.45       | 2.17 ± 1.33 | t = 41.55   | p < 0.0001 |
| BASFI, mean±SD           | 5.18 ± 2.45       | 4.27 ± 2.28 | t = 4.73    | p = 0.0315 |
| HAQ, mean±SD             | 0.83 ± 0.65       | 0.81 ± 0.56 | t = 0.02    | p = 0.8924 |
| BASDAI, mean±SD          | 6.20 ± 1.77       | 5.84 ± 1.91 | t = 1.16    | p = 0.2839 |
| ASDAS-PCR, mean±SD       | 2.99 ± 0.60       | 2.92 ± 0.48 | t = 0.45    | p = 0.5018 |

Bonferroni’s test for pairwise comparisons:

*** = p<0.0001 with respect to controls. Significant p values are reported in bold face.

https://doi.org/10.1371/journal.pone.0194693.t001

City, CA, USA) as previously described by us [29]. Representative instrumental findings are shown in S1 and S2 Figs.
analyses of TNFA SNPs were extended to all cases and controls for whom biological material was available. The following data were available: -1031 T>C SNP 228/373 controls and 136/137 patients; -857C>T SNP: 368/373 controls and 135/137 patients; -376G>A SNP: 254/373 controls and 130/137 patients; -308G>A SNP: 365/373 controls and 135/137 patients; -238G>A SNP: 356/373 controls and 137/137 patients.

**TNF-α mRNA expression analysis**

Peripheral blood mononuclear cells (PBMCs) obtained from 95 controls, 19 AS and 26 PsA were isolated by gradient centrifugation (Histopaque, 1077, Sigma-Aldrich, Milano, Italy). Total RNA from PBMCs was isolated according to the manufacturer’s instructions (High Pure RNA Isolation Kit, Roche, Germany). Five hundred ng of total RNA were reverse transcribed into cDNA (Random primers and Superscript™ II -Reverse Transcriptase, Invitrogen, Italy). Relative quantification of TNF- α was undertaken by RT-PCR with ABI Prism 7900 HT (Applied Biosystems, CA, USA) using the primers and probe set supplied by ThermoFisher Scientific (Waltham, USA, catalogue number 4331182, assay ID Hs00174128_m1). Relative quantifications were performed in a final volume of 20 μL with 33 ng of cDNA. The reference gene, HPRT1 (Hypoxanthine-guanine phosphoribosyltransferase), was selected according to the method commonly used for internal control for quantitative gene expression analyses, and its expression was determined by commercially available HPRT1 primers and probe sets (Part Number 4326321E, Applied Biosystems, CA, USA). TNF and HPRT1 were analyzed in duplicate for each sample. PCR was run at 2 minutes at 50˚C, 10 min at 95˚C, followed by 40 cycles of 15 seconds at 95˚C and 1 min at 60˚C. To determine the relative mRNA expression levels of TNF gene we used the comparative Ct method, a mathematical model that calculates changes in gene expression as a relative fold difference between an experimental and a pool derived from 20 healthy blood donors used as calibrator sample.

**Statistical analysis**

The chi-square (χ2) test, Fisher’s exact test, binary logistic regression analysis, Student’s t test for unpaired data, analysis of variance (ANOVA) and Bonferroni’s adjustment of p value for multiple testing were performed using Stata software, version 13.1 (StataCorp, Lakeway Drive, TX, USA). Genotype frequencies were tested for Hardy-Weinberg equilibrium proportions using χ2 test. Haplotypes phases and frequencies were estimated by the retrospective profile-likelihood approach using the Stata haplologit package. Odds ratio (OR) was calculated by logistic regression analysis using the additive model [31].

**Results**

**Biomarkers of inflammation in AS and PsA**

Based on the premise that inflammation of the sacroiliac joint is the hallmark of SpA, we first verified whether this confined inflammatory process could induce alterations in haematological and biochemical inflammatory indices.

The results found at enrolment in cases and controls are reported in Table 2. Both AS and PsA were associated with haematological and biochemical signs of systemic inflammation, being the number of white blood cells (WBC), polymorphonuclear cells (PMN) and platelets (PLT), and serum CRP levels increased in patients with respect to controls. PsA was also correlated with increased levels of glucose and ALT.
HLA-B27 is associated with AS

The genetic basis of SpA is complex, but the role of HLA-B27 haplotype is well established. For this reason we first evaluated in a series of 214/373 controls and 91/137 patients the HLA-B27 haplotype, results being presented in Table 3. As expected, SpA cases carrying the HLA-B27 were more frequent than controls ($\chi^2 = 120.12, p < 0.0001$), being this haplotype mainly associated with AS than with PsA.

TNFA -1031C/-308G haplotype reduces AS risk

A number of variants in genes encoding for inflammatory and immunomodulatory cytokines and for their receptors could be involved in SpA. In this study we investigated the presence of association between SpA and five SNPs in the promoter region of TNFA. These SNPs regulate singly or combined in haplotypes the transcription of TNF-α, one of the main cytokines involved in SpA pathogenesis and target of therapy with TNF-α inhibitors.

The genotypes and Minor Allele Frequency (MAF) resulting from the five studied SNPs of the TNFA gene and found in patients (AS and PsA) and controls are reported in Table 4.
All polymorphisms were in Hardy-Weinberg equilibrium (p > 0.01) and only the -1031T>C SNP was significantly correlated with disease diagnosis, with a lower number of AS cases carrying the TC or the CC genotypes.

The studied polymorphisms of the TNFA gene, all closely located in the promoter region, are carried as different haplotypes. The haplotypes and their frequencies in controls resulting from the pairwise combination of the five SNPs were inferred by statistical analysis (S2 Table).

To verify whether TNFA haplotypes exert any independent role over SpA diagnosis, logistic regression analyses were performed, on considering SpA as the outcome variable and TNFA haplotype combinations as predictors. Table 5. reports the OR with 95% confidence intervals (CI) with respect to the reference haplotype (Ref), which, for any combination, was the most frequent in controls.

The haplotype resulting from the combination of the rare TNFA -1031 C allele with the common TNFA -308 G allele was significantly associated with SpA with an OR lower than 1.00, suggesting its protective role. When SpA were considered singly, the TNFA -1031C/-308G haplotype was confirmed to be associated with AS (OR: 0.35, CI: 0.19–0.65; p < 0.001), but not with PsA (OR: 0.95, CI: 0.62–1.44; p = 0.793). Among HLA-B27 positive patients, the TNFA -1031C/-308G haplotype was confirmed to exert a protective role for AS (OR: 0.21, CI: 0.09–0.47; p < 0.001), while this was not the case of HLA-B27 negative patients (OR: 0.71, CI: 0.21–2.42; p = 0.585).

By selecting the two SNPs -1031T>C and -308G>A of the TNFA gene, the six following genotypes resulting from haplotypes combinations, were inferred: TG/TG, TG/TA, TG/CG, TA/TA, CG/TA, CG/CG. Since the most frequent TNFA haplotype was -1031T/-308G while the protective TNFA haplotype was -1031C/-308G, genotypes were grouped as follows: common homozygous (TG/TG), carriers of the protective haplotype (CG/TA, CG/CG), and others (TG/TA and TA/TA). Subjects carrying the protective TNFA -1031C/-308G

Table 4. TNFA gene polymorphisms in controls, AS and PsA patients.

| dbSNP    | MAF   | Controls |       | AS      |       | PsA     |       | Statistics |
|----------|-------|----------|-------|---------|-------|---------|-------|------------|
| TNFA gene |       | GENOTYPES | GENOTYPES | GENOTYPES | GENOTYPES |       |       |            |
|          |       | (frequency) | (frequency) | (frequency) | (frequency) |       |       |            |
| -1031T>C | C     | C/C T/C T/T | C/C T/C T/T | C/C T/C T/T |        | χ² = 11.97 |       | p = 0.018 |
| rs1799964 | (0.242) | (0.05) (0.43) (0.52) | (0.02) (0.20) (0.78) | (0.05) (0.41) (0.54) |       |       |       |            |
| -857C>T  | T     | T/T C/T C/C | T/T C/T C/C | T/T C/T C/C |        | χ² = 1.48 |       | p = 0.83 |
| rs1799724 | (0.217) | (0.05) (0.33) (0.62) | (0.07) (0.33) (0.60) | (0.04) (0.37) (0.59) |       |       |       |            |
| -376G>A  | A     | A/A G/A G/G | A/A G/A G/G | A/A G/A G/G |        | χ² = 2.69 |       | p = 0.26 |
| rs1800750 | (0.020) | (-) (0.05) (0.95) | (-) (-) (1) | (-) (0.04) (0.96) |       |       |       |            |
| -308G>A  | A     | A/A G/A G/G | A/A G/A G/G | A/A G/A G/G |        | χ² = 3.40 |       | p = 0.493 |
| rs1800629 | (0.109) | (0.01) (0.19) (0.80) | (-) (0.18) (0.82) | (-) (0.25) (0.75) |       |       |       |            |
| -238G>A  | A     | A/A G/A G/G | A/A G/A G/G | A/A G/A G/G |        | χ² = 8.43 |       | p = 0.07 |
| rs361525 | (0.055) | (-) (0.12) (0.88) | (-) (0.04) (0.96) | (0.01) (0.10) (0.89) |       |       |       |            |

Significant p values are reported in bold face.

https://doi.org/10.1371/journal.pone.0194693.t004
haplotype were less frequently found among AS (10%, \( \chi^2 = 12.674 \) and \( p = 0.002 \)), not among PsA (26%, \( \chi^2 = 0.213 \) and \( p = 0.899 \)), with respect to controls (49%).

TNF-α expression in PBMCs obtained from a series of 95 controls was found to be significantly reduced among carriers of the protective TNFA -1031C/-308G haplotype (Fig 1; Table 5. Logistic regression analyses considering SpA diagnosis as the outcome variable and TNFA haplotype combinations as predictors.

| SNP  | SNP  | TNFA haplotypes | OR (95% CI) | p    |
|------|------|-----------------|-------------|------|
| -1031T>C | -857C>T | -1031T/-857C | Ref         |      |
|       |       | -1031C/-857C | 0.69 (0.47–1.05) | 0.071 |
|       |       | -1031T/-857T | 0.99 (0.69–1.40) | 0.946 |
|       |       | -1031C/-857T | -         | -    |
| -1031T>C | -376G>A | -1031T/-376G | Ref         |      |
|       |       | -1031C/-376G | 0.71 (0.49–1.03) | 0.072 |
|       |       | -1031C/-376A | -         | -    |
|       |       | -1031T/-376A | -         | -    |
| -1031T>C | -308G>A | -1031T/-308G | Ref         |      |
|       |       | -1031C/-308G | **0.67 (0.46–0.97)** | **0.035** |
|       |       | -1031T/-308A | 0.99 (0.62–1.56) | 0.954 |
|       |       | -1031C/-308A | -         | -    |
| -1031T>C | -238G>A | -1031T/-238G | Ref         |      |
|       |       | -1031C/-238G | 0.75 (0.50–1.11) | 0.158 |
|       |       | -1031C/-238A | -         | -    |
|       |       | -1031T/-238A | -         | -    |
| -857C>T | -376G>A | -857C/-376G | Ref         |      |
|       |       | -857C/-376A | 0.49 (0.14–1.75) | 0.273 |
|       |       | -857T/-376G | 1.10 (0.78–1.54) | 0.581 |
|       |       | -857T/-376A | -         | -    |
| -857C>T | -308G>A | -857C/-308G | Ref         |      |
|       |       | -857T/-308G | 1.13 (0.80–1.60) | 0.479 |
|       |       | -857C/-308A | 1.12 (0.71–1.78) | 0.611 |
|       |       | -857T/-308A | -         | -    |
| -857C>T | -238G>A | -857C/-238G | Ref         |      |
|       |       | -857T/-238G | 1.09 (0.78–1.53) | 0.599 |
|       |       | -857C/-238A | 0.74 (0.38–1.43) | 0.367 |
|       |       | -857T/-238A | -         | -    |
| -308G>A | -376G>A | -308G/-376G | Ref         |      |
|       |       | -308A/-376G | 1.07 (0.68–1.68) | 0.751 |
|       |       | -308G/-376A | 0.47 (0.13–1.69) | 0.249 |
|       |       | -308A/-376A | -         | -    |
| -308G>A | -238G>A | -308G/-238G | Ref         |      |
|       |       | -308A/-238G | 1.03 (0.65–1.63) | 0.895 |
|       |       | -308G/-238A | 0.60 (0.30–1.22) | 0.159 |
|       |       | -308A/-238A | -         | -    |
| -238G>A | -376G>A | -238G/-376G | Ref         |      |
|       |       | -238A/-376G | 0.84 (0.37–1.86) | 0.662 |
|       |       | -238G/-376A | -         | -    |
|       |       | -238A/-376A | -         | -    |

Significant p values are reported in bold face.

https://doi.org/10.1371/journal.pone.0194693.t005

haplotype were less frequently found among AS (10%, \( \chi^2 = 12.674 \) and \( p = 0.002 \)), not among PsA (26%, \( \chi^2 = 0.213 \) and \( p = 0.899 \)), with respect to controls (49%).

TNF-α expression in PBMCs obtained from a series of 95 controls was found to be significantly reduced among carriers of the protective TNFA -1031C/-308G haplotype (Fig 1;
This association between TNFA genetics and TNF-α expression was not confirmed in SpA patients (F = 0.81, p = 0.452).

To ascertain whether other genes were involved in TNF-α signalling or in joint inflammation, we selected TNFRSF1A, which encodes the TNFR-1 of TNF-α, and MEFV, which encodes the inflammatory protein pyrin. TNFRSF1A and MEFV may affect protein function by the presence of uncommon variants. For this reason with the aim to identify any potentially relevant sequence variation, the complete sequence analyses of exons described to carry hotspot mutations more frequently, namely exons 2, 3, 4 and 6 of TNFRSF1A gene and exons 2, 3, 5 and 10 of MEFV gene, were performed. The sequence analysis of TNFRSF1A and MEFV genes were performed in an exploratory cohort of 27 controls (25 males, 2 females; mean age ± SD: 44.7 ± 11.9 years) and in 91 cases (57 males, 34 females; mean age ± SD: 52.2 ± 12.5 years).

Direct sequencing of exons 2, 3, 4 and 6 of TNFRSF1A gene allowed the identification of a total of two SNPs, the R92Q (rs4149584, exon 4) and the c.625+10 A > G (rs1800693, intron 6). None of these two polymorphisms was correlated with SpA (χ² = 1.073 and p = 0.300 for R92Q; χ² = 4.721 and p = 0.094 for c.625+10A>G) (S3 Table).

Direct sequencing of exons 2, 3, 5 and 10 of MEFV gene allowed the identification of a total of twenty-one SNPs. Among them, eleven were synonymous SNPs (exon 2: D102D, A165A,
G138G; exon 3: R314R; exon 5: E474E, D510D, Q476Q, R501R, Q489Q; exon 10: F721F, P706P), and ten were missense SNPs (exon 2: E148Q, S179N, R202Q; exon 3: P369S, R408Q, R348H; exon 5: A457V; exon 10: A744S; K695M, M680I) of potential functional significance. Among the ten identified missense SNPs, nine were extremely rare in our population, being their MAF lower or equal to 0.025. Only the R202Q SNP (rs224222) had a MAF of 0.288 and the rare homozygous AA genotype was found only among cases (AS frequency = 0.09; PsA frequency = 0.10), not in controls ($\chi^2 = 7.4837; p = 0.006$) (S4 Table). To improve the estimate of this association, the number of examined controls was extended from 27 to 218 reaching a ratio between cases and controls close to 1:2. By doing this, the association between the R202Q SNP and SpA was not confirmed ($\chi^2 = 1.05, p = 0.59$) (S5 Table).

**TNFRSF1A c.625+10A > G SNP predicts response to anti-TNFα treatment**

Therapy with TNF-α inhibitors although effective, may fail in a subset of SpA patients. Based on the hypothesis that a different genetics background underlying the TNF-α pathway may condition the clinical response, we verified whether HLA-B27, TNFA and TNFRSF1A genetics correlate with response to TNF-α inhibitors. The analysis was performed considering a subset of 65 patients who were under treatment with TNF-α inhibitors and for whom the aforementioned genetic data were available. Thirty six patients had early remission, i.e. BASDAI score lower than/equal to 4 in a time ranging from 1 to 10 months (mean ± SD: 5.94 ± 1.19 months; median: 6 months), while 29 patients were late responders, i.e BASDAI score lower than/equal to 4 in a time ranging from 10 to 36 months (mean ± SD: 16.55 ± 7.16 months; median: 12 months).

Only the TNFRSF1A c.625+10A > G SNP was associated with response to therapy, the rare GG genotype being more frequently found among late than early responders (Table 6), the association being confirmed among patients treated with infliximab (Fisher’s exact = 0.026) but not in those treated with adalimumab (Fisher’s exact = 1.000). The number of patients treated with the other TNF-α inhibitors was too low to support statistical analysis and these drugs were therefore not considered in separate analyses.

**Discussion**

The SpA are a group of chronic inflammatory diseases characterized by the sharing of distinctive pathological, clinical and radiographic aspects and a strong genetic predisposition [1]. Since no specific biomarkers of diagnosis and prognosis have been validated for the clinical assessment of these diseases [5,6], we verified whether inflammatory biochemical markers commonly used in clinical practice and genetic variants of HLA locus, TNF-TNFR pathway and MEFV play a part in increasing the risk of the most prevalent SpA subtypes, AS or PsA, and/or in predicting the response to therapy with TNF-α inhibitors.

The two SpA subtypes, as expected, were well distinguished by characteristic clinical manifestations. Family history of disease, personal history of psoriasis, dactylitis and peripheral arthritis were more frequently found among PsA, and this fit well with the CASPAR criteria [26]. Back pain and buttock pain, although commonly shared by the two disease groups, were more frequent among AS than PsA, while some extra-articular clinical manifestations were extremely rare in both groups.

In both AS and PsA, WBC, PMN, PLT and serum CRP were higher than in controls, although often comprised within the reference intervals. These minimal differences in systemic signs of inflammation between cases and controls might depend on treatment (all patients were on TNF-α inhibitors or nonsteroidal anti-inflammatory drugs-NSAIDs/disease-
modifying antirheumatic drugs- DMARDS) and indicate that the systemic inflammatory process, underlying these diseases, cannot be completely switch off [32].

The main genetic determinant of SpA, HLA-B27, was confirmed in the present study to be strictly associated with AS, and less strictly with PsA [33]. Located in proximity of the HLA genes, the TNFA gene appears of potential interest in SpA. Five main polymorphisms in the promoter region of this gene have been described in Caucasians and reported to be associated with different inflammatory and autoimmune diseases [34,35]. Considering the specific SpA setting, data in the literature are not definitive and sometimes contrastive, not only because of differences in ethnicity, number and selection criteria of the studied populations, but also

| Table 6. HLA alleles, TNFA and TNFRSF1A genetics and response to TNF-α inhibitors. |
|-----------------------------------------------|-----------------------------------------------|
|                                              | Early responders | Late responders |
|                                              | n (%)            | n (%)            | χ²          | p          |
| **HLA-B27**                                  |                  |                  |             |            |
| Negative                                     | 22 (33.8%)       | 20 (30.8%)       | χ² = 0.4334 | p = 0.510  |
| Positive                                     | 14 (21.5%)       | 9 (13.8%)        |             |            |
| **TNFA**                                     |                  |                  |             |            |
| -1031T>C                                     |                  |                  |             |            |
| T/T                                          | 23 (35.4%)       | 17 (26.1%)       | χ² = 0.1960 | p = 0.907  |
| T/C                                          | 11 (16.9%)       | 10 (15.4%)       |             |            |
| C/C                                          | 2 (3.1%)         | 2 (3.1%)         |             |            |
| -857C>T                                      |                  |                  |             |            |
| T/C                                          | 14 (22.2%)       | 8 (12.7%)        | p = 0.111   |            |
| T/T                                          | 0 (0.0%)         | 3 (4.8%)         |             |            |
| -376G>A                                      |                  |                  |             |            |
| G/G                                          | 34 (55.7%)       | 26 (42.6%)       | χ² = 0.7552 | p = 0.385  |
| G/A                                          | 1 (1.6%)         | 0 (0.0%)         |             |            |
| A/A                                          | -                | -                |             |            |
| -308G>A                                      |                  |                  |             |            |
| G/G                                          | 30 (47.6%)       | 20 (31.7%)       | χ² = 0.8077 | p = 0.369  |
| G/A                                          | 6 (9.5%)         | 7 (11.1%)        |             |            |
| A/A                                          | -                | -                |             |            |
| -238G>A                                      |                  |                  |             |            |
| G/G                                          | 33 (50.8%)       | 27 (41.5%)       | χ² = 0.0467 | p = 0.829  |
| G/A                                          | 3 (4.6%)         | 2 (3.1%)         |             |            |
| A/A                                          | -                | -                |             |            |
| **TNFRSF1A**                                 |                  |                  |             |            |
| R92Q                                         |                  |                  |             |            |
| G/G                                          | 35 (53.8%)       | 26 (40%)         | χ² = 1.5925 | p = 0.207  |
| G/A                                          | 1 (1.5%)         | 3 (4.6%)         |             |            |
| A/A                                          | -                | -                |             |            |
| c.625+10A>G                                  |                  |                  |             |            |
| A/A                                          | 13 (20%)         | 5 (7.7%)         | χ² = 6.9648 | p = 0.031  |
| G/A                                          | 18 (27.7%)       | 12 (18.5%)       |             |            |
| G/G                                          | 5 (7.7%)         | 12 (18.5%)       |             |            |

Significant p values are reported in bold face.

https://doi.org/10.1371/journal.pone.0194693.t006
because these SNPs regulate TNFA gene transcription mainly acting as haplotypes, which were verified in this study. Only TNFA -1031T>C SNP was associated with SpA diagnosis, while the other studied SNPs were not, this finding being in agreement with previous data [8]. The haplotypes deriving from the pairwise combinations of the five studied SNPs were inferred and only the haplotype -1031C/-308G was significantly associated with SpA, exerting in these diseases a protective role, which was mainly for AS and confirmed also among HLA-B27 positive patients. This protective role might be explained taking into account that any single allele concurring in determining the studied haplotype was demonstrated to be associated with reduced TNF-α release. In fact, the rare -1031C allele, in complete linkage disequilibrium with the -863A allele, associates with low TNF-α production [36], and the -308G common allele associates with a lower spontaneous or stimulated TNF-α release both in vitro and in vivo with respect to the rare -308A allele [37,38]. The hypothesis that TNFA -1031C/-308G haplotype might determine a reduced TNF-α transcription was confirmed in this study by the analysis of mRNA expression levels in PBMCs obtained from healthy subjects. However, in the presence of diseases, the dampened TNF-α expression associated with TNFA -1031C/-308G haplotype was not seen. It is not surprising because of the limited sample size and the complicate situations of patients, such of treatment of TNF-α inhibitors. Based on the above data, it is reasonable to suggest that the TNFA -1031C/-308G haplotype exerts a protective role for SpA, but mainly for AS, in HLA-B27 positive subjects by limiting the transcription of TNF-α.

In the complex scenario of TNF-α effects in inflammation and autoimmunity one might bear in mind the role of TNF-α receptors, which genetic variability might underlies complex autoimmune inflammatory diseases such as TRAPS [17]. Only a few number of variants of TNFRSF1A, encoding for the TNFR-1, were detected in our studied population and none of them was associated with the diagnosis of AS or PsA. Therefore, in the absence of copy number variation or other mutations, a role for TNFRSF1A genetics in SpA could be reasonably excluded.

Other genes involved in the inflammation processes, as genes encoding cytokines (e.g. IL23R, IL17, IL2R) or proteins of the inflammasome pathway (e.g. CARD9, CARD14, CARD16) have been reported as associated with SpA in several studies [9,39]. An interesting candidate involved in inflammasome pathway is MEFV gene, encoding for the protein pyrin, critically involved in the autoinflammatory disease FMF and recently suggested as potentially involved also in SpA [18–24]. Several MEFV variants were identified in our studied population, half without functional significance and half with potential functional consequences for the predicted amino acid substitutions in the protein. These variants were however sporadic and none was associated with SpA diagnosis. Intriguingly the main MEFV variant that has been demonstrated to be associated with AS, namely the M694V [21,23,24], was never recorded among our series of patients. These apparent discrepant results are probably consequent to differences in ethnicity (Italian vs Turkish) and in patient’s selection criteria (SpA patients in our series vs FMF patients with AS in the Turkish series).

One of the main problems in the clinical setting of SpA is the interindividual variability in response to therapy, mainly in response to TNF-α inhibitors [40–42]. Different drugs belonging to this category are now available and they are frequently used to treat both AS and PsA especially when NSAIDs or DMARDS are not beneficial [43,44]. In this study about 88% AS and 59% PsA were on treatment with TNF-α inhibitors, and among them 11% AS and 19% PsA required in their disease history the switch from one to at least another drug type for an incomplete response to treatment. This empirical approach is the only one actually proposed since no predictive response biomarkers are validated. Their identification is really necessary also considering the high costs for the health care system of this type of therapy [45]. Among factors that might affect variability in response to therapy, genetics should be considered besides physiological (age, sex, weight, and body fat), pathophysiological (liver, kidney, and
cardiovascular function, and associated diseases), and environmental factors (tobacco and alcohol consumption and concomitant treatments) [46–48]. In our series carriers of rare c.625 +10 G allele of TNFRSF1A gene were mainly late responders. This polymorphism might affect the response to TNF-α inhibitors because it is associated with an altered TNF-α/TNFR1 balance. In fact, patients carrying the rare G allele have been suggested to synthesize a truncated TNFR-1 [49], and the common A allele was previously demonstrated by us to be correlated with increased serum TNF-α levels in patients with celiac disease [30].

Although a limitation of this study is represented by the lack of complete genetic data for all enrolled patients and controls, any group of data were obtained by a significant number of patients and controls. Future perspectives are confirmatory studies on genetics as predictor of the response to TNF-α inhibitors. In this setting, besides TNFRSF1A, many other genes of the TNF/TNFR pathway and of related pathways should be considered and comprehensively investigated possibly through new technologies, like next generation sequencing, in large series of patients to support clinical translation of results.

In conclusion the results of this study indicate the relevant role of TNF-TNFR pathway genetics in the complex network causing SpA and conditioning response to therapy. TNFA was shown to be a predisposing factor for SpA, but mainly for AS, among Italian patients, while genetics of the autoinflammatory gene MEFV appears of no impact in this setting. The haplotype resulting from TNFA-1031T/-308G, associated with lower TNF-α production, exerts a protective role in AS, while the TNFRSF1A c.625+10A>G polymorphism emerged as a potential predictor of response to TNF-α inhibitors.

Supporting information

S1 Fig. Genotype discrimination of the TNFA -857 C>T SNP. Images show the representative TaqMan amplification curves of samples homozygous C/C, heterozygous C/T and homozygous T/T obtained using 857 C (upper) and T (lower) probes separately. Allelic discrimination scatter plot for the TNFA -857 C>T is shown on the right. (TIF)

S2 Fig. Allelic discrimination scatter plots. Allelic discrimination scatter plots for the TNFA gene SNPs: -1031T>C and -376G>A (upper panel), -308G>A and -238G>A (lower panel). (TIF)

S1 File. Materials and methods. MEFV gene analysis. (DOC)

S1 Table. Primer sequences for the amplification of exons 2, 3, 5 and 10 of the MEFV gene. (DOC)

S2 Table. TNFA haplotypes combinations: Frequencies inferred from controls. The Table reports the haplotypes combinations (and their respective frequencies) statistically inferred from the pairwise combination of TNFA-1031T>C, -857C>T, -376G>A, -308G>A and -238G>A polymorphisms in control subjects. (DOC)

S3 Table. TNFRSF1A gene polymorphisms in controls and cases (AS and PsA). Results from the exploratory study. Table reports the genotypes and Minor Allele Frequency (MAF) resulting from the two SNPs, identified in patients (AS and PsA) and controls (explanatory group), through the DHPLC screening of exons 2, 3, 4 and 6 of the TNFRSF1A gene followed by direct sequence analysis of positive samples. (DOC)
S4 Table. *MEFV* gene missense polymorphisms in controls and in cases (AS and PsA patients). Results from the exploratory study. Table reports the genotypes and Minor Allele Frequency (MAF) resulting from the ten missense polymorphisms, identified in patients (AS and PsA) and controls (explanatory group), through the direct sequencing of exons 2, 3, 5 and 10 of *MEFV* gene.

(DOC)

S5 Table. R202Q polymorphism in the entire studied population. Table reports the genotypes and Minor Allele Frequency (MAF) resulting from the genotype discrimination of the R202Q SNP (rs224222) in *MEFV* gene (exon 2), in the entire studied population.

(DOC)

Author Contributions

Conceptualization: Ada Aita, Daniela Basso, Roberta Ramonda.

Data curation: Ada Aita, Roberta Ramonda, Stefania Moz, Mariagrazia Lorenzin, Filippo Navaglia, Carlo-Federico Zambon.

Formal analysis: Ada Aita, Daniela Basso, Stefania Moz, Filippo Navaglia, Carlo-Federico Zambon.

Funding acquisition: Leonardo Punzi.

Investigation: Ada Aita, Daniela Basso, Roberta Ramonda, Mariagrazia Lorenzin.

Methodology: Ada Aita, Filippo Navaglia, Carlo-Federico Zambon.

Project administration: Ada Aita, Daniela Basso.

Software: Andrea Padoan.

Supervision: Daniela Basso, Mario Plebani, Leonardo Punzi.

Validation: Daniela Basso, Mario Plebani, Leonardo Punzi.

Visualization: Stefania Moz.

Writing – original draft: Ada Aita.

Writing – review & editing: Daniela Basso, Roberta Ramonda, Mario Plebani, Leonardo Punzi.

References

1. Garg N, van den Bosch F, Deodhar A. The concept of spondyloarthritis: where are we now? Best Pract Res Clin Rheumatol. 2014; 28:663–72. https://doi.org/10.1016/j.berh.2014.10.007 PMID: 25488776

2. Stolwijk C, van Onna M, Boonen A, van Tubergen A. Global Prevalence of Spondyloarthritis: AS systematic Review and Meta-Regression Analysis. Arthritis Care Res. 2016; 68:1320–31.

3. Turina MC, Landewe R, Baeten D. Lessons to be learned from serum biomarkers in psoriasis and IBD —the potential role in SpA. Expert Rev Clin Immunol. 2017; 13:333–44. https://doi.org/10.1080/1744666X.2017.1244004 PMID: 27705027

4. Moz S, Aita A, Basso D, Ramonda R, Plebani M, Punzi L. Spondyloarthritis: Matrix Metalloproteinase-3 Biomarkers of Pathogenesis and Response to Tumor Necrosis Factor (TNF) Inhibitors. Int J Mol Sci. 2017; 18:830–44.

5. Feldtkeller E, Khan MA, van der Heijden D, van der Linden S, Braun J. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int. 2003; 23:61–6. https://doi.org/10.1007/s00296-002-0237-4 PMID: 12634937
6. Van der Heijde D, Landewé R, Einstein S, Ory P, Vosse D, Ni L, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 2008; 58:1324–31. https://doi.org/10.1002/art.23471 PMID: 18438853

7. Chatzikiariakidou A, Voulgaris PV, Drosos AA. What is the role of HLA-B27 in spondyloarthropathies? Autoimmun Rev. 2011; 10:464–8. https://doi.org/10.1016/j.autrev.2011.01.011 PMID: 21296192

8. Lee YH, Song GG. Lack of association of TNF-alpha promoter polymorphisms with ankylosing spondylitis: a meta-analysis. Rheumatology. 2009; 48:1359–62. https://doi.org/10.1093/rheumatology/kep260 PMID: 19720680

9. Australo-Anglo-American Spondyloarthritis Consortium (TASC), Reveille JD, Sims AM, Danoy P, Evans DM, Leo P, et al. Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci. Nat Genet. 2010; 42:123–7. https://doi.org/10.1038/ng.513 PMID: 2062062

10. Pointon JJ, Harvey D, Karaderi T, Appleton LH, Farrar C, Stone MA, et al. The chromosome 16q region associated with ankylosing spondylitis includes the candidate gene tumour necrosis factor receptor type 1-associated death domain (TRADD). Ann Rheum Dis. 2010; 69:1243–6. https://doi.org/10.1136/ard.2009.115147 PMID: 19854717

11. O’Rielly DD, Rahman P. Genetics of psoriatic arthritis. Best Pract Res Clin Rheumatol. 2014; 28:673–20. Cosan F, Ustek D, Oku B, Duymaz-Tozkir J, Cakiris A, Abaci N, et al. Association of familial Mediterranean fever gene mutations in ankylosing spondylitis: a meta-analysis. Clin Rheumatol. 2010; 29:983–90. https://doi.org/10.1007/s10067-010-1499-y PMID: 20535510

12. Robinson PC, Brown MA. Genetics of ankylosing spondylitis. Mol Immunol. 2014; 57:2–11. https://doi.org/10.1016/j.molimm.2013.06.013 PMID: 23916070

13. Van Kuijk AW, Reinders-Blankert P, Smeets TJ, Dijkmans BA, Tak PP. Detailed analysis of the cell infiltration and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis. 2006; 65:1551–7. https://doi.org/10.1136/ard.2005.050963 PMID: 16728461

14. Li B, Wang P, Li H. The association between TNF-alpha promoter polymorphisms and ankylosing spondylitis. Clin Rheumatol. 2010; 29:85–9. https://doi.org/10.1007/s10067-010-1499-y PMID: 20535510

15. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006; 54:2665–73. https://doi.org/10.1002/art.21972 PMID: 16871531
27. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic andbiological disease-modifying anti-rheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73:492–509. https://doi.org/10.1136/annrheumdis-2013-204573 PMID: 24161836

28. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D; ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis. 2006; 65:316–20. https://doi.org/10.1136/ard.2005.040758 PMID: 16096329

29. Zambon CF, Basso D, Navaglia F, Belluco C, Falda A, Fogar P, et al. Pro- and anti-inflammatory cytokines gene polymorphisms and Helicobacter pylori infection: interactions influence outcome. Cytokine. 2005; 29:141–52. https://doi.org/10.1016/j.cyto.2004.10.013 PMID: 15652446

30. Rossi E, Basso D, Zambon CF, Navaglia F, Greco E, Pelloso M, et al. TNFA Haplotype Genetic Testing Improves HLA in Estimating the Risk of Celiac Disease in Children. PLoS One. 2015; 10:e0123244. https://doi.org/10.1371/journal.pone.0123244 PMID: 25915602

31. Marchenko YV, Carroll RJ, Lin DY, et al. Semiparametric analysis of case–control genetic data in the presence of environmental factors. Stata Journal Volume 8 Number 3; 2008.

32. Coates LC, FitzGerald O, Hellwell PS, Paul C. Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same? Semin Arthritis Rheum. 2016. pii: S0049-0172:30064–6.

33. López de Castro JA. HLA-B27 and the pathogenesis of spondyloarthropathies. Immunol Lett. 2007; 108:27–33. https://doi.org/10.1016/j.imlet.2006.10.004 PMID: 17129613

34. Chung WT, Choe JY, Jang WC, Park SM, Ahn YC, Yoon IK, et al. Polymorphisms of tumor necrosis factor-α promoter region for susceptibility to HLA-B27-positive ankylosing spondylitis in Korean population. Rheumatol Int. 2011; 31:1167–75. https://doi.org/10.1007/s00296-010-1434-1 PMID: 20349238

35. El-Tahan RR, Ghoneim AM, El-Mashad N. TNF-α gene polymorphisms and expression. Springerplus. 2016; 5:1508. https://doi.org/10.1186/s40064-016-3197-y PMID: 27652081

36. Skoog T, van’t Hooft FM, Kallin B, Jovinge S, Boquist S, Nilsson J, et al. A common functional polymorphism (C→A substitution at position -863) in the promoter region of the tumour necrosis factor-alpha (TNF-alpha) gene associated with reduced circulating levels of TNF-alpha. Hum Mol Genet. 1999; 8:1443–9. PMID: 10400991

37. Rudwaleit M, Siegert S, Yin Z, Eick T, Thiel A, Radbruch A, et al. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Ann Rheum Dis. 2001; 60:36–42. https://doi.org/10.1136/ard.60.1.36 PMID: 11114280

38. Elahi MM, Asotra K, Matata BM, Mastana SS. Tumor necrosis factor alpha -308gene locus promoter polymorphism: an analysis of association with health and disease. Biochim Biophys Acta. 2009; 1792:163–72. PMID: 19708125

39. Brown MA. Genetics of ankylosing spondylitis. Curr Opin Rheumatol. 2010; 22:126–32. https://doi.org/10.1097/BOR.0b013e3283364483 PMID: 20084006

40. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004; 63:665–70. https://doi.org/10.1136/ard.2003.016386 PMID: 15037444

41. Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis. 2011; 70:973–81. Erratum in: Ann Rheum Dis. 2012;71:1434. https://doi.org/10.1136/ard.2010.147744 PMID: 21402563

42. Maneiro JR, Souto A, Salgado E, Mera A, Gomez-Reino JJ. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis. RMD Open 2015; 18:1–e00017.

43. Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70:896–904. https://doi.org/10.1136/ard.2003.016386 PMID: 15037444

44. Baraliakos X, van den Berg R, Braun J, van der Heijde D. Update of the literature review on treatment with biologics as a basis for the first update of the ASAS/EULAR management recommendations of ankylosing spondylitis. Rheumatology. 2012; 51:1378–87. https://doi.org/10.1093/rheumatology/ker026 PMID: 22427410

45. McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, et al. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation. Health Technol Assess. 2007; 11:1–158.

46. Schiotis R, Sánchez A, Escudero A, Bartolomé N, Szczypiorska M, Font P, et al. Candidate’s single-nucleotide polymorphism predictors of treatment nonresponse to the first anti-TNF inhibitor in
47. Song GG, Seo YH, Kim JH, Choi SJ, Ji JD, Lee YH. Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthritis, psoriasis and Crohn’s disease: a meta-analysis. Pharmacogenomics. 2015; 16:1427–37. https://doi.org/10.2217/pgs.15.90 PMID: 26244882

48. Liu J, Dong Z, Zhu Q, He D, Ma Y, Du A, et al. TNF-α Promoter Polymorphisms Predict the Response to Etanercept More Powerfully than that to Infliximab/Adalimumab in Spondyloarthritis. Sci Rep. 2016; 6:32202. https://doi.org/10.1038/srep32202 PMID: 27578555

49. Ottoboni L, Frohlich IY, Lee M, Healy BC, Keenan BT, Xia Z, et al. Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013; 81:1891–9. https://doi.org/10.1212/01.wnl.0000436612.66328.8a PMID: 24174586